Up to 30% of patients with refractory ulcerative colitis have steroid-resistant disease and, if cured with restorative proctocolectomy, could develop pouchitis. Ciclosporin and infliximab monotherapy have been used experimentally to tackle this problem. A recent study has assessed ciclosporin and infliximab as second-line therapies when one has failed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Leblanc, S. et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am. J. Gastroenterol. 106, 771–777 (2011).
Faubion, W. A. Jr, Loftus, E. V. Jr, Harmsen, W. S., Zinsmeister, A. R. & Sandborn, W. J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121, 255–260 (2001).
Hueting, W. E., Buskens, E., van der Tweel, I., Gooszen, H. G. & van Laarhoven, C. J. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig. Surg. 22, 69–79 (2005).
Actis, G. C., Fadda, M., David, E. & Sapino, A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long-term retrospective cohort study. BMC Gastroenterol. 7, 13 (2007).
Arts, J. et al. Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 10, 73–78 (2004).
Gustavsson, A. et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis—3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment. Pharmacol. Ther. 32, 984–989 (2010).
Lichtenstein, G. R. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621–630 (2006).
Cheifetz, A. S. et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J. Clin. Gastroenterol. 45, 107–112 (2011).
Laharie, D. et al. Cyclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. J. Crohns Colitis 5, S8 (2011).
Maser, E. A. et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6, 1112–1116 (2008).
Arijs, I. et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612–1619 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Daperno has been a speaker and consultant for Abbott Laboratories and Merck-MSD. He has been a speaker for Chiesi Farmaceutica, Giuliani, Ferring and Sofar Farma. G. C. Actis declares no competing interests.
Rights and permissions
About this article
Cite this article
Actis, G., Daperno, M. Rescue immune suppression for severe colitis—worth the risk?. Nat Rev Gastroenterol Hepatol 8, 303–304 (2011). https://doi.org/10.1038/nrgastro.2011.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.86